Adult BMI Calculator

The standard WHO cutoffs were derived primarily from White/European populations. Decades of evidence show that Asian, South Asian, and certain African-origin populations accumulate proportionally more visceral fat and experience elevated metabolic risk at lower BMI values. A universal BMI ≥ 30 threshold therefore misses many at-risk individuals in these groups.

The WHO Expert Consultation (2004) recommended an overweight threshold of BMI ≥ 23 for Asian populations. A 19-year London cohort (Tillin et al., PMC4441277) found diabetes risk equivalent to BMI 30 in Europeans occurred at BMI 25.2 for South Asians and 27.2 for African-Caribbeans.

The following tables present the classification system used by this calculator. Thresholds are inclusive at the lower bound and exclusive at the upper bound (except the final class).

🌍 Chinese / East Asian

Recommended by the Working Group on Obesity in China, consistent with WHO Asia-Pacific guidance.

🌏 South-East Asian

Aligned with WHO Asia-Pacific recommendations (Malaysia, Indonesia, Thailand, Vietnam, Philippines, Singapore, etc.).

🌍 African

Applied to individuals of sub-Saharan African descent; evidence for this group is still evolving.

🌏 South Asian / Indian

Endorsed by the Consensus Statement for Asian Indians (Misra et al.) and consistent with IDF guidance for South Asians.

Using the Global/Western standard: BMI ≥ 30.0 is Obesity (Class I), with substantially increased risk of Type 2 diabetes, cardiovascular disease, hypertension, and certain cancers. BMI ≥ 35.0 is Class II, with a markedly elevated comorbidity burden. BMI ≥ 40.0 is Severe Obesity (Class III), associated with significantly reduced life expectancy and possible bariatric-surgery evaluation.

For Asian, South-East Asian, and South Asian populations, these thresholds shift downward by 2–5 BMI points — e.g., a South Asian individual at BMI 27.5 is classified Obese Class I and should be evaluated accordingly.

BMI does not distinguish fat mass from lean mass. Because muscle is denser than fat, athletes, bodybuilders, and regular strength trainers can register as "overweight" or even "obese" despite very low body fat. A PLOS ONE NHANES analysis (PMC5894968) found that at any BMI ≥ 22, individuals with low muscle mass had higher body fat, more diabetes, and higher all-cause mortality — the same BMI carries different risk depending on body composition.

No — BMI measures weight relative to height, not adiposity. A landmark study of 13,601 NHANES III participants (PMC2877506) found BMI had high specificity (95% men, 99% women) but poor sensitivity (36% men, 49% women) for body-fat-defined obesity, concluding that BMI "misclassifies ≥ 50% of patients with excess body fat as normal or just overweight." The CDC notes BMI is "moderately to strongly associated" with body fat — making it a screening, not diagnostic, instrument.

The same BMI value represents different body composition by sex. For any given BMI, women typically carry a higher body-fat percentage, while men accumulate more harmful visceral fat. A 2024 sex-specific Mendelian randomization study (PMC12158425, 194,174 women / 167,020 men) found BMI more strongly associated with myocardial infarction and coronary heart disease in men, and with apolipoprotein B and diastolic blood pressure in women — concluding there is a need for "nuanced, sex-specific policy related to BMI."

BMI cutoffs do not change with age for adults over 20, but the underlying body composition does. Muscle mass declines roughly 1% per year from middle age, so an older adult at the same BMI as a younger one typically carries more fat and less muscle. A 2022 International Journal of Obesity study (DOI: 10.1038/s41366-022-01069-4) found standard WHO cutpoints may not accurately reflect risk in adults 65+, where overweight BMI may even confer a survival advantage.

In June 2023 the American Medical Association adopted a landmark policy recognizing BMI's limitations and recommending it no longer be used in isolation. The AMA noted BMI cutoffs are "based primarily on data collected from previous generations of non-Hispanic white populations," that BMI "loses predictability when applied on the individual level," and urged using it alongside measures such as visceral fat, waist circumference, and body composition.

The formula was developed by Belgian mathematician Adolphe Quetelet in the 1830s–1840s as a statistical descriptor of human morphology (the "Quetelet Index"), not a clinical tool. The term "Body Mass Index" and its clinical use were popularized by physiologist Ancel Keys in a 1972 paper. As a 2024 review (PMC11204233) confirms, BMI was "developed originally from a single sample of White, middle-aged European men."

In 1998 the U.S. NIH/NHLBI aligned with the WHO standard, lowering the overweight threshold from BMI ≥ 27.8 (men) / ≥ 27.3 (women) to a unified BMI ≥ 25. Overnight, roughly 29 million Americans were reclassified as "overweight." The 1998 NIH Clinical Guidelines remain the foundation of current US practice.

As of 2025 the consensus is: not replaced entirely, but substantially supplemented and contextualized. BMI remains valuable for population surveys and primary screening but is limited for predicting individual chronic-disease risk. Leading complements include waist circumference, waist-to-hip ratio, body fat percentage (DEXA/BIA), relative fat mass (RFM), and body volume index (BVI). Any replacement must match BMI's zero-cost simplicity at scale.

Obesity significantly increases the risk of coronary artery disease, atrial fibrillation, heart failure, and sudden cardiac death — risk that is proportional to BMI and worsened by hypertension and dyslipidemia. The association between elevated BMI and Type 2 diabetes is among the strongest in metabolic epidemiology, and South Asian, Chinese, and Black populations develop diabetes at lower BMI ranges. Globally, higher-than-optimal BMI was responsible for an estimated 3.7 million NCD deaths in 2021.

Visceral fat releases pro-inflammatory cytokines and free fatty acids that impair insulin sensitivity, raise blood pressure, elevate triglycerides, and suppress HDL cholesterol. Per StatPearls, individuals with abdominal obesity have higher morbidity and mortality. The 2024 sex-specific study (PMC12158425) found BMI especially associated with diastolic blood pressure and apolipoprotein B in women, and ischemic heart disease in men.

In some clinical populations — heart failure, coronary disease, chronic kidney disease, and older adults — those in the overweight or mildly obese range appear to have better survival than those of "normal" weight. Likely explanations include greater metabolic reserve during illness, the fact that low BMI in older/ill adults often reflects muscle wasting (sarcopenia), and BMI's inability to capture fat-to-muscle ratio. This is why the AMA, WHO, and CDC recommend interpreting BMI alongside waist circumference and body composition.

As of 2024–2025, FDA-approved GLP-1 weight-loss medications use BMI thresholds (Global/Western standard):

Qualifying comorbidities include high blood pressure, dyslipidaemia, Type 2 diabetes, and obstructive sleep apnea. Medication decisions should always be made with a licensed healthcare provider.

The WHO uses BMI as its primary global tracking metric while endorsing lower cutoffs for Asian populations. The CDC advises considering BMI alongside blood pressure, cholesterol, and physical examination. The AMA (2023) recommends BMI be used "in conjunction with other valid measures of risk." The UK's NICE guidelines apply lower action thresholds (≥ 23 overweight, ≥ 27.5 obesity) for South Asian, Chinese, and other Asian adults.

Waist circumference is the single most recommended complement — men ≥ 94 cm / women ≥ 80 cm signal increased risk (lower for Asian populations). Waist-to-hip ratio (> 0.90 men, > 0.85 women) captures fat distribution. Body fat percentage (DEXA, BIA, calipers) directly measures adiposity (obesity > 25% men, > 35% women). Relative fat mass (RFM) and visceral fat assessment (CT/MRI/advanced BIA) provide further detail BMI cannot.

For most adults aged 20–65, a BMI within the healthy range for your ethnic group is the general goal; research suggests the upper-normal to lower-overweight range (~22–27 for Western populations) is associated with the lowest all-cause mortality in middle-aged and older adults. The CDC recommends routine tracking; every 6–12 months is sufficient for most healthy adults. A single reading is a snapshot — the trajectory over time matters more.

Most people achieve their greatest weight loss in the first 3–6 months of a lifestyle program, making early momentum critical. A loss of just 5–10% of body weight (4.5–9 kg for a 90 kg person) produces clinically significant reductions in blood pressure, fasting glucose, and triglycerides — even if BMI remains in the overweight category.

Diet: prioritise whole, minimally processed foods; a 500–750 kcal/day deficit yields ~0.5–0.75 kg/week with better muscle preservation; Mediterranean and low-carbohydrate patterns both have strong evidence; reduce ultra-processed foods and sugar-sweetened beverages.

Activity: ≥ 150–300 min/week moderate (or 75–150 min vigorous) aerobic activity, plus ≥ 2 resistance sessions/week to preserve muscle — directly addressing one of BMI's blind spots.

Behaviour: self-monitoring, 7–9 hours of sleep (regulating leptin and ghrelin), and stress management (cortisol promotes visceral fat) all improve outcomes.

Consult a healthcare professional if your BMI is Obese Class I+ for your ethnic group (or overweight with risk factors); if you are underweight (< 18.5) with fatigue or deficiencies; if your BMI has risen 2–3 points in 12 months unexplained; if you are considering weight-loss medication or surgery; if you are pregnant or planning to be (standard BMI does not apply); or if you are an athlete with elevated BMI needing body-composition testing (DEXA/BIA).